The Rubin lab approach to cancer research has grown in parallel with the rapid expansion of bioinformatics and sequencing technology over the past 10 years. Our expertise in identifying functional biomarkers and investigating prostate cancer heterogeneity has led to key discoveries in the distinction between indolent and aggressive cancer types. Our mission is to identify potential therapeutic targets and bridge the latest in cancer genetics research with individual patient oriented clinical care. The Rubin lab is based in Bern at the Department for BioMedical Research (DBMR), University of Bern, Switzerland.
Prostate Cancer Challenge Award awarded to Mark Rubin, MD (University of Bern) and George Coukos, MD, PhD (University of Lausanne)
Immune-Radiation Therapy for Metastatic Castration-Resistant Prostate Cancer (testing the combination of radiation therapy and immunotherapy for the treatment of advanced prostate cancer, and identify biomarkers and mechanisms of treatment response).